Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Annexon Inc (ANNX)

Annexon Inc (ANNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 551,508
  • Shares Outstanding, K 119,633
  • Annual Sales, $ 0 K
  • Annual Income, $ -138,200 K
  • EBIT $ -219 M
  • EBITDA $ -216 M
  • 60-Month Beta 1.20
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.06

Options Overview Details

View History
  • Implied Volatility 124.39% (+4.74%)
  • Historical Volatility 104.30%
  • IV Percentile 37%
  • IV Rank 12.81%
  • IV High 553.56% on 04/16/25
  • IV Low 61.35% on 01/13/25
  • Expected Move (DTE 12) 0.85 (18.44%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 959
  • Volume Avg (30-Day) 784
  • Put/Call OI Ratio 0.38
  • Today's Open Interest 19,836
  • Open Int (30-Day) 14,979
  • Expected Range 3.76 to 5.46

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.32
  • Number of Estimates 4
  • High Estimate -0.29
  • Low Estimate -0.36
  • Prior Year -0.33
  • Growth Rate Est. (year over year) +3.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.54 +81.50%
on 11/13/25
5.07 -9.07%
on 11/20/25
+1.60 (+53.16%)
since 11/05/25
3-Month
2.10 +119.52%
on 09/10/25
5.07 -9.07%
on 11/20/25
+2.44 (+112.44%)
since 09/05/25
52-Week
1.28 +260.16%
on 04/10/25
5.66 -18.55%
on 01/03/25
-0.46 (-9.07%)
since 12/05/24

Most Recent Stories

More News
Annexon Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million

BRISBANE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across...

ANNX : 4.61 (+2.67%)
Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across...

ANNX : 4.61 (+2.67%)
Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing...

ANNX : 4.61 (+2.67%)
Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Late-Stage Neuroinflammation Platform Advancing Global Registrational Programs in  Guillain-Barré Syndrome ( GBS) and Geographic Atrophy (GA) Current Tanruprubart GBS Dossier On Track for MAA...

ANNX : 4.61 (+2.67%)
Annexon Biosciences to Participate in Upcoming September Investor Conferences

BRISBANE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating...

ANNX : 4.61 (+2.67%)
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating...

ANNX : 4.61 (+2.67%)
Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Tanruprubart (formerly ANX005) for GBS Advancing Through Regulatory Interactions; MAA Submission in Europe Anticipated in First Quarter of 2026; Ongoing Discussions with FDA Regarding Generalizability...

ANNX : 4.61 (+2.67%)
Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy

New Pilot Appoints Designated Product Development Coordinator to Navigate Regulatory Interactions, Respond to Ad-hoc Queries, and Support Evidence Planning Vonaprument Selected by EMA as One of ~20...

ANNX : 4.61 (+2.67%)
New Strong Sell Stocks for July 22nd

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Belite Bio BLTE is a clinical stage biopharmaceutical drug development company which focused on novel therapeutics targeting currently...

BLTE : 150.00 (-0.84%)
DDD : 2.16 (-4.00%)
ANNX : 4.61 (+2.67%)
Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)

ANNX : 4.61 (+2.67%)

Business Summary

Annexon Inc. is a clinical-stage biopharmaceutical company. It engages in developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company's product candidate includes ANX005 and ANX007, which are in clinical stage. Annexon Inc....

See More

Key Turning Points

3rd Resistance Point 5.00
2nd Resistance Point 4.87
1st Resistance Point 4.74
Last Price 4.61
1st Support Level 4.48
2nd Support Level 4.35
3rd Support Level 4.22

See More

52-Week High 5.66
Last Price 4.61
Fibonacci 61.8% 3.99
Fibonacci 50% 3.47
Fibonacci 38.2% 2.95
52-Week Low 1.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar